戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 xiety, appetite loss, physical symptoms, and restlessness.
2 t, physical activity, smoking, and tenseness/restlessness.
3 ssociated ipsilateral autonomic features and restlessness.
4  termination of the procedure due to patient restlessness.
5 fferential diagnosis of genital symptoms and restlessness, along with nonmotor wearing off and akathi
6 ed temporary behavioural changes as shown by restlessness and abdominal stretchings but did not resul
7 al and death-related thoughts, hopelessness, restlessness and agitation, insomnia and impulsiveness a
8 netic involuntary movements, including motor restlessness and chorea, slowing of voluntary movements
9 s evolutionary selection but may also induce restlessness and greed.
10 ors (e.g. A2aR) in the brain responsible for restlessness and painlessness, may attenuate the behavio
11 he most central symptoms, while 'Sad mood', 'Restlessness', and 'Motor disturbance' were the most fre
12   The incidences of somnolence, weight gain, restlessness, and extrapyramidal symptoms were similar i
13 rval, and behaviours indicative of distress, restlessness, and general activity were scored and inclu
14 otor symptoms such as impaired motor skills, restlessness, and inability to relax exhibited high cent
15             Aggression, anger, irritability, restlessness, and strange dreams increased significantly
16 ales used to monitor parkinsonism, akathisia/restlessness, anxiety, depression, suicidality and somno
17 re was less insomnia, fatigue, sedation, and restlessness associated with cognitive behavioral therap
18 eports" for high, drug effects, anxiety, and restlessness), cardiovascular (pulse rate and diastolic
19 f age) with assessment of insomnia symptoms (restlessness, difficulty falling asleep, waking at night
20 /-4, P < or = 0.02; E2: +4+/-4, P = 0.1) and restlessness (E1: +4+/-4, P < or = 0.04; E2: +4+/-5, P =
21 pecific physical and psychological symptoms (restlessness, fatigue, difficulty concentrating, irritab
22 ed findings of previous studies on migratory restlessness in whooper swans.
23 sociations across emotional, behavioral, and restlessness/inattention problems; 18% to 60% of childre
24 rder is characterised by feelings of threat, restlessness, irritability, sleep disturbance, and tensi
25        In the scopolamine vs placebo groups, restlessness occurred in 22 of 79 patients (28%) vs 18 o
26 which included difficulty in falling asleep, restlessness of sleep, daytime sleepiness, sleep disturb
27 sleepiness, and 1.44 (95% CI, 1.36-1.53) for restlessness of sleep.
28 remors (two episodes), apnea (two episodes), restlessness (one episode).
29  commonly retro-orbital, pain accompanied by restlessness or agitation, and cranial (parasympathetic)
30 bserved that the Btbd9 mutant mice had motor restlessness, sensory alterations likely limited to the
31 s (fatigue, gastrointestinal upset/diarrhea, restlessness/sleep disturbances, minor wheezing, and col
32 ritis, increased appetite, increased weight, restlessness, tendon disorder, and potential drug-induce
33 dition sleep more and exhibit less migratory restlessness than birds in good condition do.
34 and less irritability, anxiety, craving, and restlessness than placebo.
35 ural symptoms (e.g. feelings of anxiety, and restlessness) using data from 14,959 genotyped family tr
36                              The presence of restlessness was the most important clinical feature in
37 isms, and behavioral indicators of migratory restlessness were studied in wintering whooper swans (Cy